Today: 30 April 2026
AST SpaceMobile stock drops nearly 9% as Vanguard stake filing hits tape; traders eye late-February launch
30 January 2026
1 min read

AST SpaceMobile stock drops nearly 9% as Vanguard stake filing hits tape; traders eye late-February launch

New York, January 30, 2026, 15:09 EST — Regular session

  • AST SpaceMobile shares dropped roughly 8.7% to $111.50, having swung from a 6% gain to an 11% loss earlier.
  • In an amended Schedule 13G filing, The Vanguard Group revealed it held a 7.68% stake as of Dec. 31
  • Investors have their eyes on a late-February BlueBird 7 launch aboard Blue Origin’s New Glenn-3 mission

AST SpaceMobile shares dropped roughly 8.7% to $111.50 in afternoon trading Friday, after kicking off the session at $121.10. The stock saw wild swings, hitting a high of $129.74 and plunging to a low of $109.04, as over 16 million shares traded hands.

The pullback follows a sharp surge that turned the Nasdaq-listed stock into a trader favorite. The company is developing a space-based cellular broadband network aimed at linking straight to regular mobile phones. Reuters data reveals it pulled in $4.4 million in revenue this year but recorded a net loss near $300 million.

Vanguard disclosed in a regulatory filing on Friday that it owned 21,488,180 shares of AST SpaceMobile as of Dec. 31, amounting to 7.68% of the company’s common stock. This update appeared in an amended Schedule 13G, a form used by major investors to report holdings once they exceed 5%. Vanguard clarified the stake was held in the ordinary course of business and not intended to influence control.

In another filing on Jan. 28, UBS revealed a $1.55 million issuance of “trigger autocallable” notes tied to AST SpaceMobile shares, maturing in 2029. These bank-backed notes are structured debt designed to pay coupons if the stock remains above specified thresholds and may be called early under certain triggers, the pricing supplement showed.

Neither filing points to a new equity raise by AST SpaceMobile, but both add to the growing paper trail on a stock known for wild gap moves and heavy derivatives activity. For many investors, the pressing question remains: can the company meet its milestones to transform a satellite plan into a revenue-generating service.

AST SpaceMobile has set its sights on the next orbital milestone: BlueBird 7, slated for late February from Cape Canaveral Space Force Station aboard Blue Origin’s New Glenn-3 rocket, a Jan. 22 press release via Business Wire revealed. “This launch advances our mission to bring space-based cellular broadband connectivity to everyday smartphones as we progress towards launching commercial services in 2026,” said Scott Wisniewski, the company’s president. He noted the schedule could still shift. Business Wire

The downside remains clear-cut. A delay in the launch window, weaker-than-anticipated commercial uptake, or fresh funding demands could shake risk appetite once more, especially following a recent period of sharp swings.

Traders will be keeping an eye on whether the stock stabilizes following Friday’s volatility and if new regulatory filings reveal more about recent ownership changes. The next major event to watch is the BlueBird 7 launch window on New Glenn-3, scheduled for late February.

Stock Market Today

  • Why This ASX 200 Biotech Stock Is Under Pressure
    April 30, 2026, 3:23 PM EDT. The ASX 200 biotech sector is facing pressure amid recent market developments. Key factors include regulatory challenges and clinical trial setbacks affecting investor sentiment. This volatility impacts stock valuations and trading volumes, highlighting risks within the biotech industry. Investors are advised to monitor updates carefully and consult financial professionals before making decisions. Recent movements underscore the sector's sensitivity to news flow and operational progress.

Latest article

Rezolve AI Stock Rises After Revenue Tops All of 2025 in 90 Days

Rezolve AI Stock Rises After Revenue Tops All of 2025 in 90 Days

30 April 2026
Rezolve AI reported $60 million in first-quarter revenue, surpassing its audited 2025 total of $46.8 million, based on unaudited accounts. Shares rose 4.9% after the update. The company reaffirmed its $360 million 2026 revenue target and said it can reach profitability without new equity sales. Commerce.com, which rejected Rezolve’s all-stock takeover offer, adopted a poison pill defense.
Option Care Health Stock Plunges After 2026 Revenue Cut Exposes Chronic-Therapy Drag

Option Care Health Stock Plunges After 2026 Revenue Cut Exposes Chronic-Therapy Drag

30 April 2026
Option Care Health shares fell 28% to $19.44 after the company cut its 2026 revenue forecast and reported first-quarter sales of $1.35 billion, missing estimates. The company now expects 2026 revenue of $5.675–$5.775 billion, down from a prior range of $5.8–$6.0 billion, citing pressure in its chronic inflammatory disease portfolio. Adjusted profit guidance was unchanged.
Stellantis N.V. Stock Slides: Q1 Profit Rebound Leaves One Big Cash-Flow Question

Stellantis N.V. Stock Slides: Q1 Profit Rebound Leaves One Big Cash-Flow Question

30 April 2026
Stellantis reported a first-quarter net profit of €377 million, reversing a €387 million loss a year earlier, aided by a €400 million expected U.S. tariff refund. Industrial free cash flow remained negative at €1.92 billion. Shares fell 6.4% to €6.22 after the results. CEO Antonio Filosa faces pressure ahead of a May 21 investor day to present a stronger turnaround plan.
Procter & Gamble stock rises as Wall Street turns defensive — what traders watch next
Previous Story

Procter & Gamble stock rises as Wall Street turns defensive — what traders watch next

Honeywell stock cools after earnings pop as breakup clock and 2026 outlook take center stage
Next Story

Honeywell stock cools after earnings pop as breakup clock and 2026 outlook take center stage

Go toTop